Navigation Links
Pharma and food thought leaders set to converge in Amsterdam next April
Date:8/20/2010

Amsterdam, 20 August 2010 - Pharma-Nutrition, the new international scientific conference organised by Elsevier, the leading publisher of scientific, technical and medical information products and services, aims to discuss the latest research, concepts and practical applications of medical nutrition in patient treatments, disease management and patient outcomes. Pharma-Nutrition is set to take place next 18-20 April at Amsterdam's NH Grand Hotel Krasnapolsky. The convergence of both pharmacology and food science professionals, will make this the first platform dedicated to the scientific interface between pharma and food.

The Scientific Committee composed of acknowledged opinion leaders in both food science and pharmacology from across the spectrum of therapeutic research areas will work alongside organisers to develop a multidisciplinary programme, covering areas such as oncology, immunology, neurology and cardiovascular disease. The Conference Chairman, Professor Johan Garssen, University of Utrecht, commented, "We are starting to see a real convergence of the two areas of pharma and food and it is their complementary values which can be applied to medical nutrition in order to help address the ever growing burden of diseases in modern society."

"I am so pleased that we have been able to bring together for the first time such an outstanding group of preclinical and clinical experts from both pharma and nutrition," said Dr. Jaap van Harten, Elsevier Executive Publisher. "This conference will provide the platform for participants to share and discuss their latest research on this important area of science," he remarked.


'/>"/>

Contact: Rachel Martin
r.martin@elsevier.com
31-020-485-2467
Elsevier
Source:Eurekalert

Page: 1

Related biology news :

1. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
2. Pitt pharmacologists go on a molecular fishing trip and hook prize catch
3. ACS Green Chemistry Institute Pharmaceutical Roundtable award goes to Scottish chemist
4. ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
5. Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule
6. URI pharmacy researcher finds beneficial compounds in pure maple syrup
7. NIH awards $8.5 million for research on pharmaceuticals for children
8. TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
9. GREENBioPharma -- Dec. 2-3, 2009
10. ERGONEX Pharma receives Frost & Sullivans European Orphan Diseases Entrepreneurial Company Award 2009
11. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:5/6/2016)... ... 06, 2016 , ... Crucial Life Sciences Data Solutions, Inc. ... improves performance of the platform. In particular, Version 4.1 boosts performance for complex ... to be collected on a per patient basis. Clinical Studio has employed a ...
(Date:5/5/2016)... ... May 05, 2016 , ... American Process, Inc. (API) announced ... Patent Nos. 9,322,133 and 9,322,134, to API and its affiliated companies for BioPlus® ... hydrophobic nanocellulose compositions. In addition to these patents and U.S. Patent No. ...
(Date:5/4/2016)... ... 05, 2016 , ... CereScan, the nation’s leader in providing ... National Stroke Awareness Month in May. An infographic created by CereScan will ... CereScan will donate $1 up to a maximum of $3,000 through users who ...
(Date:5/4/2016)... 4, 2016  Bayer today announced that a ... ® (regorafenib) tablets for the treatment of ... its primary endpoint of a statistically significant improvement ... the efficacy and safety of regorafenib in patients ... with sorafenib. The safety and tolerability were generally ...
Breaking Biology Technology: